Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer)

摘要

Sir, Recently in this journal, we reported the primary efficacy and safety results from the single-arm OCTAVIA study evaluating the combination of bevacizumab, car-boplatin and weekly paclitaxel as front-line treatment for ovarian cancer [1]. At the primary PFS analysis, median progression-free survival (PFS) was 23.7 months (90% confidence interval [CI] 19.9-26.4 months; 95% CI 19.8-26.4 months; PFS events in 52% of patients) in the overall population and 18.1 months (95% CI 16.0— 19.6 months; PFS events in 69% of patients) in the subgroup at high risk of progression (original ICON7 definition [2]).